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Rationale: Gender-related differences in asthma prevalence, pathophysiology and
clinical features induced by sex steroids have been investigated, however, how gender
influences response to asthma treatments in routine clinical practice have not yet been
elucidated fully. This aspect is crucial for montelukast considering the jeopardization
of asthmatic patients that benefit from this treatment and the existence of evidence
of gender differences in leukotriene levels. Therefore, to fulfill this medical need, we
investigated the role of gender on a set of montelukast’ effectiveness surrogates in adults
and pediatric patients with asthma.
Methods: The study settings were Napoli 2 Local Health Unit (southern Italy) and
the entire Danish territory. The study population was composed of adult and pediatric
patients with asthma. Cumulative incidence curves, unadjusted and adjusted Cox
regression were used as statistical models to compare aforementioned outcomes
between genders.
Results: Adult Italian male users of montelukast had a statistically lower persistence
in montelukast treatment compared to female users. In the adjusted analyses, they
had a higher hazard of montelukast’ withdrawal (Hazard Ratio [HR] 1.07; 95%
Confidence Interval [CI] 1.01–1.14), add-on/switch to a long-term treatment for asthma
following montelukast withdrawal (HR 1.72; 95%CI 1.39–2.12), and rescue therapy
with short-acting β2 agonist (HR 1.24; 95%CI 1.04–1.47). In the adult Danish cohort,
we also found that male users had higher a hazard of rescue therapy with oral
corticosteroids (HR 1.10; 95%CI 1.04–1.16). In the pediatric cohorts, no statistically
significant differences were observed between genders for aforementioned outcomes.
Sessa et al. Gender Differences in the Effectiveness of Montelukast
Conclusions: In adults, male gender was associated with increased hazards of
montelukast discontinuation, add-on/switch to a long-term treatment for asthma
following montelukast withdrawal, and rescue therapy with oral corticosteroids or short-
acting β2 agonist when compared to the female gender. As expected, these associations
were reversed or absent in pediatric patients.
Keywords: clinical epidemiology, asthma, humans, pharmacoepidemiology, pharmacology, translational medical
research, montelukast
INTRODUCTION
Gender-related differences in asthma prevalence, patho-
physiology and clinical features induced by sex steroids have
been investigated, however, how gender influences response to
asthma treatments in routine clinical practice have not yet been
elucidated fully (Hanley, 1981; Eliasson et al., 1986; Postma,
2007; Pignataro et al., 2017).
In the last decade, new milestones have been set to
understand the biological pathways in which sex steroids are
involved in determining gender differences in asthma. Pioneering
experiments performed by Pergola and colleagues proved that in
stimulated whole blood, testosterone and 5α-dihydrotestosterone
were able to modulate leukotriene biosynthesis by activating
extracellular signal-regulated kinases (ERKs). In turn, ERK
represses phospholipase D, causing a reduced biosynthesis of
leukotriene by 5-lipoxygenase. These phenomena lead to higher
blood concentrations of leukotrienes in women’s blood than men
(Pergola et al., 2008, 2011).
Additionally, experiments on preclinical models showed
an impaired modulation of leukotriene pathway mediated by
androgens in male rats and mice that unbalanced the rate
of severe asthma exacerbation between the two genders when
both were exposed to leukotriene biosynthesis inhibitors. This
effect was abolished by administrating blood or leukocytes
with 5α-dihydrotestosterone to female mice and rats suggesting
a potential gender difference mediated by sex steroids in
the effectiveness of the pharmacological treatment with anti-
leukotriene between male and female (Pace et al., 2017).
Accordingly, clinical studies investigating the impact of sex
steroids in asthma exacerbation during menstrual cycle found
that modification of sex steroids levels was associated with
a higher concentration of inflammatory biomarkers, including
serum leukotriene B4/C4 (Skobeloff et al., 1996; Nakasato et al.,
1999; Rossi et al., 2014).
These phenomena might be crucial for montelukast, the
most used leukotriene receptor antagonist in several European
countries (Sen et al., 2011; Henriksen et al., 2017). Montelukast,
in fact, antagonizes the cysteinyl leukotriene receptor CysLT1 in
the lungs and bronchial tubes preventing the biological effects
mediated by leukotriene D4 (and secondary ligands, leukotrienes
C4 and E4) (Paggiaro and Bacci, 2011; Hon et al., 2014).
Understanding if gender is a key predictor for anti-leukotriene
treatment’ effectiveness is pivotal considering the jeopardization
of asthmatic patients that benefit from leukotriene receptor
antagonist, whose population, to date, it is not well characterized
(Helms, 2000; Borish, 2002; Nayak, 2004; Chauhan et al., 2013,
2017; Bush, 2015; Cingi et al., 2015; Marcello and Carlo, 2016;
Pyasi et al., 2016). Moreover, providing new evidence for gender
differences in asthma’ treatment is needed considering that
clinical studies investigating aforementioned associations are
missing (Pignataro et al., 2017).
Therefore, given the paucity of evidence on this topic,
we investigated the role of gender on a set of montelukast’
effectiveness surrogates in adults and pediatric patients with
asthma.
METHODS
Data Sources
For the purpose of this study, we used both Napoli Second
Local Health Unit (Campania Region, Italy) and Danish
administrative databases. Napoli Second Local Health Unit
administrative database was set up in December 2014, and
currently, contains information on 1,051,883 individuals living
in the catchment area of Naples and registered on the lists of 761
general practitioners. Collected information included patients’
demographic characteristics, the cause of hospital admission
coded according to the International Classification of Disease,
9th revision (ICD-9), and drug prescription classified according
to the Anatomical Therapeutic Chemical (ATC) classification
system. By using medical diagnoses leading to pharmacological
prescriptions and causes of hospital admission, we were able to
obtain information on patients’ concurrent comorbidities. For
each prescription, in fact, general practitioners were required
to code medical diagnoses for the aforementioned prescription
that was coded according to ICD-9. Therefore, Napoli Second
Local Health Unit administrative database allowed us to track
anonymously hospital access, clinical and drug history routinely
collected for each patient from December 2014 to June 2017.
For Danish registries instead, we were able to obtain the same
information for the entire Danish population by using the Danish
Civil Registration System, the Danish National Causes of Death
Registry, the Danish National Patient Registry, and the Danish
Registry of Medicinal Product Statistics. The original role and
composition of each Danish administrative registry are fully
recognized in clinical epidemiology and it is described elsewhere
(Gaist et al., 1997; Helweg-Larsen, 2011; Lynge et al., 2011).
Italian Study Population
The Italian study population was composed of patients with
asthma treated with montelukast for the first time from June
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TABLE 1 | Baseline characteristics of Italian/Danish adult patients with asthma at the first prescription of montelukast.
Danish Population Italian Population
Variable Level Female
(n= 12,059)
Male
(n = 6,927)
Total
(n = 18,986)
p-value Female
(n = 6,870)
Male
(n = 4,824)
Total
(n= 11,694)
p-value
Socio Economic
Status
Quartile 1 3222 (26.7) 1525 (22.0) 4747 (25.0) - - -
Quartile 2 3098 (25.7) 1649 (23.8) 4747 (25.0) - - -
Quartile 3 2918 (24.2) 1828 (26.4) 4746 (25.0) - - -
Quartile 4 2821 (23.4) 1925 (27.8) 4746 (25.0) < 0.001 - - -
Age mean (SD) 50.6 (16.8) 50.1 (16.8) 50.5 (16.8) 0.048 53.5 (21.9) 53.1 (26.6) 53.3 (24.0) 0.384
Asthma duration mean (SD) 6.6 (7.6) 7.4 (8.0) 6.9 (7.7) <0.001 - - -
Heart failure Yes 1090 (9.0) 788 (11.4) 1878 (9.9) <0.001 611(8.9) 555 (11.5) 1166 (10.0) <0.001
Chronic kidney
disease
Yes 372 (3.1) 275 (4.0) 647 (3.4) 0.001 227 (3.3) 217 (4.5) 444 (3.8) <0.001
β-blockers Yes 510 (4.2) 262(3.8) 772 (4.1) 0.143 1300 (18.9) 656 (13.6) 1956 (16.7) <0.001
Nonsteroidal
anti-inflammatory
drug
Yes 1362 (11.3) 556 (8.0) 1918 (10.1) <0.001 1067 (15.5) 454 (9.4) 1521 (13.0) <0.001
Antibiotics-
systemic
Yes 3704 (30.7) 1695 (24.5) 5399 (28.4) <0.001 2882 (42.0) 1775 (36.8) 4657 (39.8) <0.001
Low-dose
acetylsalicylic acid
Yes 568 (4.7) 337 (4.9) 905 (4.8) 0.655 364 (5.3) 214 (4.4) 578 (4.9) 0.038
β2 agonist short
acting-inhalers
Yes 8397 (69.6) 4982 (71.9) 13379 (70.5) <0.001 2169 (31.6) 1576 (32.7) 3745 (32.0) 0.218
β2 agonist short
acting-oral
Yes 853 (7.1) 501 (7.2) 1354 (7.1) 0.703 0 (0.0) 0 (0.0) 0 (0.0) 1.000
β2 agonist long
acting-inhalers
Yes 4343 (36.0) 2371 (34.2) 6714 (35.4) 0.014 497 (7.2) 292 (6.1) 789 (6.7) 0.013
β2 agonist long
acting-oral
Yes 182 (1.6) 113 (1.6) 300 (1.6) 0.712 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Glucorticoids Yes 8008 (66.4) 4561 (65.8) 12569 (66.2) 0.439 4035 (58.7) 2649 (54.9) 6684 (57.2) <0.001
Glucorticoid + β2
agonist
Yes 4571 (37.9) 2673 (38.6) 7244 (38.2) 0.359 3843 (55.9) 2189 (45.4) 6032 (51.6) <0.001
β2 agonist
(non-selective)
Yes 5 (0.0) 4 (0.1) 9 (0.0) 0.880 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Mast-cell stabilizer Yes 44 (0.4) 36 (0.5) 80 (0.4) 0.142 111 (1.6) 50 (1.0) 161 (1.4) 0.010
1, 2015 to June 30, 2017. A patient was defined as treated
with montelukast for asthma if he/she redeemed a prescription
for a drug with an ATC code R03DC03 or R03DC53 and
the prescription had 493 (the ICD-9 code) as the cause for
montelukast prescription. The date of the first redeeming of
such prescription was used as the index date for each patient. In
all, two cohorts were retrieved from the Italian population, the
Italian pediatric cohort or rather patients with an age<18 years at
the first prescription of montelukast and the Italian adult cohort
or rather patients with an age ≥18 years at the first prescription
of montelukast.
Danish Study Population
All patients with a diagnosis of asthma from January 1, 1995
to December 31, 2012 that were treated for the first time
with montelukast were identified in the Danish registries. We
defined a patient as having a diagnosis of asthma if he/she
had primary or secondary hospitalization diagnoses coded as
J45 or J46 in accordance with ICD-10 or as ICD-8 codes 493.
The diagnosis of asthma has been validated in the Danish
Patient Registry (specificity of 98%) (Jensen AØ et al., 2010).
A patient was defined as being treated with montelukast if
he/she had redeemed prescriptions of a drug with an ATC
code R03DC03 or R03DC53. The date of the first redeeming
of such prescription was used as the index date for each
patient. As for the Italian population, the Danish population was
divided in the Danish pediatric cohort and in the Danish adult
cohort.
Follow-Up Period
The Danish population was followed in administrative registries
from the index date to censoring for death or on December 31,
2012 while the Italian population up to June 30, 2017 due to data
availability. To estimate the period of exposure to montelukast,
the ongoing exposure was calculated for each individual by
dividing the number of posological units dispensed by the
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TABLE 2 | Baseline characteristics of Italian/Danish pediatric patients with asthma at the first prescription of montelukast.
Danish Population Italian Population
Variable Level Female
(n = 4,173)
Male
(n = 6,778)
Total
(n = 10,951)
p-value Female
(n = 4,572)
Male
(n = 6,653)
Total
(n= 11,225)
p-value
Socio Economic
Status
Quartile 1 830 (19.9) 1425 (21.0) 2255 (20.6) - - -
Quartile 2 429 (10.3) 535 (7.9) 964 (8.8) - - -
Quartile 3 607 (14.5) 907 (13.4) 1514 (13.8) - - -
Quartile 4 754 (18.1) 953 (14.1) 1707 (15.6) - - -
Missing 1553 (37.2) 2958 (43.6) 4511 (41.2) <0.001 - - -
Age mean (SD) 8.2 (5.2) 7.1 (4.8) 7.5 (5.0) <0.001 6.8 (4.1) 7.2 (4.3) 7.0 (4.2) <0.001
Asthma duration mean (SD) 3.2 (3.7) 3.3 (3.6) 3.3 (3.6) 0.234 - - -
Nonsteroidal
anti-inflammatory
drug
Yes 39 (0.9) 21 (0.3) 60 (0.5) <0.001 1067 (15.5) 454 (9.4) 1521 (13.0) <0.001
Antibiotics-
systemic
Yes 832 (19.9) 1365 (20.1) 2197 (20.1) 0.818 2882 (42.0) 1775 (36.8) 4675 (39.8) <0.001
β2 agonist short
acting-inhalers
Yes 3209 (76.9) 5326 (78.6) 8535 (77.9) 0.042 2756 (60.3) 4152 (62.4) 6908 (61.5) 0.024
β2 agonist short
acting-oral
Yes 211 (5.1) 395 (5.8) 606 (5.5) 0.095 0 (0.0) 0 (0.0) 0 (0.0) 1.000
β2 agonist long
acting-inhalers
Yes 566 (13.6) 768 (11.3) 1334 (12.2) <0.001 11 (0.2) 13 (0.2) 24 (0.2) 0.763
β2 agonist long
acting-oral
Yes 0 (0.0) 0 (0.0) 0 (0.0) 1.000 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Glucorticoids Yes 3191 (76.5) 5370 (79.2) 8561 (78.2) <0.001 3908 (85.5) 5636 (84.7) 9544 (85.0) 0.277
Glucorticoid + β2
agonist
Yes 728 (17.4) 1051 (15.5) 1779 (16.2) <0.001 586 (12.8) 1054 (15.8) 1640 (14.6) <0.001
β2 agonist
(non-selective)
Yes 0 (0.0) 0 (0.0) 0 (0.0) 1.000 0 (0.0) 0 (0.0) 0 (0.0) 1.000
Mast-cell stabilizer Yes 3 (0.1) 7 (0.1) 10 (0.1) 0.894 69 (1.5) 113 (1.7) 182 (1.6) 0.481
estimated average dosage for asthma indication as described
elsewhere (Andersson et al., 2012).
Outcomes
The study outcomes were: (1) the withdrawal of montelukast;
(2) the add-on or switch to a long-term treatment for asthma
following montelukast withdrawal, and (3) the redemption of
oral corticosteroids prescription within 12 months from the
redemption of the first montelukast prescription. Moreover, (4)
the redemption of inhaled short-acting β2 agonist prescription
within 12 months from the redemption of the first montelukast
prescription. A patient was defined as receiving an add-on or
switch to a long-term treatment for asthma if he/she redeemed
prescriptions of one or more of the following drugs: inhaled
selective β2-adrenoreceptor agonists, inhaled glucocorticoids,
mast cell stabilizer, inhaled glucocorticoids + selective β2-
adrenoreceptor agonists, phosphodiesterase inhibitors (xanthine
derivatives) or mast cell stabilizer + selective β2-adrenoreceptor
agonists. ATC codes used to define aforementioned drug classes
were provided in Supplementary Table 1.
Study Covariates
Age, gender, year, and month of inclusion, asthma duration,
socioeconomic status, comorbidities, and co-treatment were
obtained at index date. Comorbidities and co-treatment were
evaluated considering all pharmacological prescriptions, hospital
access and all medical diagnosis leading to a pharmacological
prescription prior or equal to index date. Socioeconomic status
was based on family income in the year of inclusion in the
cohort and it was divided in quartile. Details on operative
definition of comorbidities and co-treatments were provided in
Supplementary Tables 2, 3.
Statistical Analyses
At index date, baseline characteristics of men and women
were compared using the t-tests or ANOVA for continuous
variables and χ2 or Fisher’s exact test for categorical variables.
All analyses were based on intention-to-treat approach and
used a statistically significant level of p < 0.05 (2-sided).
In the unadjusted analyses, cumulative incidence curves were
generated to compare cumulative incidence for aforementioned
study outcomes between genders. Grey’s test was used to
evaluate the hypotheses that cause-specific cumulative functions
were equal for male and females (Austin et al., 2016).
Time to event for each study outcome was computed as
restricted mean time or median for male and female users of
montelukast (Zhao et al., 2016). Additionally, in the unadjusted
analysis, Cox regression with only outcome and exposure was
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FIGURE 1 | Italian Population. (A) Cumulative incidence for montelukast withdrawal—comparison between adult male and female patients. (B) Cumulative incidence
for an add-on or switch to a long-term treatment for asthma following montelukast withdrawal—comparison between adult male and female patients. (C) Cumulative
incidence for montelukast withdrawal—comparison between pediatric male and female patients. (D) Cumulative incidence for an add-on or switch to a long-term
treatment for asthma following montelukast withdrawal—comparison between pediatric male and female patients.
used to compare the hazard for aforementioned outcomes
between genders. In the adjusted analyses, multivariable Cox
regression with aforementioned study covariates was used to
evaluate the effect of gender variable upon aforementioned
outcomes.
Compliance With Ethical Standards
In Italy and Denmark, register-based retrospective studies do
not require ethical approval. Patient records/information was
anonymized and de-identified prior to data analysis.
RESULTS
Baseline characteristics of adults and pediatric patients are
provided in Tables 1, 2, respectively. Cause-specific cumulative
incidence curves for male and female users of montelukast in the
Italian/Danish cohorts are provided in Figures 1–4.
Gender Differences in the Hazard of
Montelukast Withdrawal
Italian and Danish male users had a statistically lower persistence
in montelukast treatment compared to female users and a
higher hazard of montelukast’ withdrawal. In the pediatric Italian
cohort, the association was reversed. In fact, male users had
a higher persistence in montelukast treatment if compared to
female users and a lower hazard of montelukast’ withdrawal.
In the pediatric Danish population, instead, no statistically
significant differences were observed between male and female
users of montelukast (Tables 3, 4).
Gender Differences in the Hazard of
Add-on/Switch of/To a Long-Term
Treatment for Asthma Following
Montelukast Withdrawal
In both Italian and Danish cohorts, male users of montelukast
had a lower restricted mean time free from add-on or switch
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FIGURE 2 | Italian Population. (A) Cumulative incidence for rescue therapy with oral corticosteroids among montelukast users—comparison between adult male and
female patients. (B) Cumulative incidence for rescue therapy with selective β2-adrenoreceptor agonists (SABA) among montelukast users—comparison between
adult male and female patients. (C) Cumulative incidence for rescue therapy with oral corticosteroids among montelukast users—comparison between pediatric male
and female patients. (D) Cumulative incidence for rescue therapy with SABA among montelukast users—comparison between pediatric male and female patients.
to a long-term treatment for asthma following montelukast
withdrawal compared to women and a higher hazard for this
outcome (Tables 3, 4). No statistically significant differences were
observed between male and female for pediatric cohorts. Add-
on or switch performed in Italian and Danish populations are
provided in Table 5.
Gender Differences in the Hazard of
Receiving Rescue Therapies With Oral
Corticosteroids Within 12 Months From the
Redemption of the First Montelukast
Prescription
Within 12 months from the redemption of the first montelukast
prescription, Italian male users had a lower restricted mean time
free from rescue therapy with oral corticosteroids compared
to female users and a higher hazard for this outcome in the
unadjusted analysis but not in the adjusted analysis. Danish male
users of montelukast, instead, had a lower restricted mean time
free from rescue therapy with oral corticosteroids if compared
to female users and a higher hazard for this outcome. In the
Italian and Danish pediatric cohorts, no statistically significant
differences were observed between male and female users of
montelukast (Tables 3, 4).
Gender Differences in the Hazard of
Receiving Rescue Therapies With
Short-Acting β2 Agonist Within 12 Months
From the Redemption of the First
Montelukast Prescription
Within 12 months from the redemption of the first montelukast
prescription, Italian and Danish male users had a lower restricted
mean time free from rescue therapy with short-acting β2
agonist and compared to female users and a higher hazard for
this outcome. For pediatric cohorts, no statistically significant
differences were observed between Italian and Danish male and
female users of montelukast (Tables 3, 4).
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FIGURE 3 | Danish Population. (A) Cumulative incidence for montelukast withdrawal—comparison between adult male and female patients. (B) Cumulative incidence
for an add-on or switch to a long-term treatment for asthma following montelukast withdrawal—comparison between adult male and female patients. (C) Cumulative
incidence for montelukast withdrawal—comparison between pediatric male and female patients. (D) Cumulative incidence for an add-on or switch to a long-term
treatment for asthma following montelukast withdrawal—comparison between pediatric male and female patients.
FIGURE 4 | Danish Population. (A) Cumulative incidence for rescue therapy with oral corticosteroids among montelukast users—comparison between adult male and
female patients. (B) Cumulative incidence for rescue therapy with selective β2-adrenoreceptor agonists (SABA) among montelukast users—comparison between
adult male and female patients. (C) Cumulative incidence for rescue therapy with oral corticosteroids among montelukast users—comparison between pediatric male
and female patients. (D) Cumulative incidence for rescue therapy with SABA among montelukast users-comparison between pediatric male and female patients.
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TABLE 3 | Comparison between male and female users of montelukast for: (1)
persistence in montelukast treatment; (2) restricted mean time free from add-on or
switch to a long-term treatment for asthma; (3) restricted mean time free from
rescue therapy with oral corticosteroids and (4) restricted mean time free from
rescue therapy with rescue therapy with short-acting β2 agonists.
Cohorts Estimates in months
PERSISTENCE IN MONTELUKAST TREATMENT
Italian–male-adults Median 12.80; 95%CI 12.30–13.30
Italian–female-adults Median 13.87; 95%CI 13.37–14.47
Danish–male-adults Median 33.37; 95%CI 31.27–35.27
Danish–female-adults Median 40.77; 95%CI 39.2–42.70
Italian–male-pediatrics Median 12.57; 95%CI 11.47–12.53
Italian–female-pediatrics Median 11.90; 95%CI 11.47–12.53
Danish–male-pediatrics Median 23.90; 95%CI 22.87–25.00
Danish–female-pediatrics Median 24.73; 95%CI 23.33–26.10
RESTRICTED MEAN TIME FREE FROM ADD-ON OR SWITCH TO
A LONG-TERM TREATMENT FOR ASTHMA
Italian–male-adults Mean 22.7; standard error 0.09
Italian–female-adults Mean 23.0; standard error 0.07
Danish–male-adults Mean 172; standard error 1.15
Danish–female-adults Mean 175; standard error 0.83
Italian–male-pediatrics Mean 22.7; standard error 0.10
Italian–female-pediatrics Mean 23.0; standard error 0.07
Danish–male-pediatrics Mean 169; standard error 0.78
Danish–female-pediatrics Mean 172; standard error 0.55
RESTRICTED MEAN TIME FREE FROM RESCUE THERAPY WITH
ORAL CORTICOSTEROIDS
Italian–male-adults Mean 9.48; standard error 0.08
Italian–female-adults Mean 9.70; standard error 0.06
Danish–male-adults Mean 11.30; standard error 0.03
Danish–female-adults Mean 11.40; standard error 0.02
Italian–male-pediatrics Mean 9.58; standard error 0.06
Italian–female-pediatrics Mean 9.52; standard error 0.07
Danish–male-pediatrics Mean 11.8; standard error 0.03
Danish–female-pediatrics Mean 11.7; standard error 0.05
RESTRICTED MEAN TIME FREE FROM RESCUE THERAPY WITH
RESCUE THERAPY WITH SHORT-ACTING β2 AGONISTS
Italian–male-adults Mean 11.20; standard error 0.05
Italian–female-adults Mean 11.40; standard error 0.03
Danish–male-adults Mean 11.30; standard error 0.03
Danish–female-adults Mean 11.40; standard error 0.02
Italian–male-pediatrics Mean 10.80; standard error 0.05
Italian–female-pediatrics Mean 10.60; standard error 0.06
Danish–male-pediatrics Mean 7.37; standard error 0.09
Danish–female-pediatrics Mean 7.40; standard error 0.10
DISCUSSION
To our knowledge, this is the first study providing evidence of
gender differences in the persistence with montelukast treatment,
in the probability of receiving an add-on/switch of/to a long-term
treatment for asthma, and in the probability of receiving a rescue
therapy with oral corticosteroids or short-acting β2 agonist in
adult patients with asthma. TA
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TABLE 5 | Drugs added or switched following montelukast withdrawal.
Danish Population Italian Population
ATC‡ code Active
ingredients
Adults Pediatrics Adults Pediatrics
Add-on
N
†
= 1395
Switch
N
†
= 513
Add-on
N
†
= 296
Switch
N
†
= 173
Add-on
N
†
= 380
Switch
N
†
= 270
Add-on
N
†
= 264
Switch
N
†
= 390
R03AC12 salmeterol 99 (7.1) 23 (4.48) 13 (4.39) 1 (0.26)
R03AC13 formoterol 167 (12.00) 45 (8.77) 53 (17.94) 17 (9.82) 8 (2.1) 4 (1.49)
R03AK adrenergic +
corticosteroid
9 (2.36) 5 (1.86) 3 (1.16) 3 (0.76)
R03AK04 salbutamol +
cromoglicate
26 (1.86) 7 (1.36)
R03AK06 salmeterol +
fluticasone
200 (14.34) 99 (19.29) 21 (7.09) 26 (15.05) 33 (8.75) 21 (7.78) 7 (2.66) 8 (2.06)
R03AK07 formoterol +
budesonide
260 (18.64) 124 (24.22) 47 (15.87) 49 (28.32) 8 (2.1) 13 (4.82) 1 (0.387) 6 (1.54)
R03AK08 formoterol +
beclometasone
35 (9.21) 25 (9.26) 5 (1.89) 2 (0.52)
R03AK11 formoterol +
fluticasone
15 (3.94) 4 (1.49) 3 (0.77)
R03BA01 beclometasone 29 (2.07) 21 (4.09) 26 (8.78) 10 (5.78) 117 (30.78) 106 (39.26) 91 (34.46) 140 (35.91)
R03BA02 budesonide 317 (22.72) 104 (20.27) 75 (25.33) 33 (19.07) 30 (7.89) 25 (9.25) 53 (20.07) 103 (26.42)
R03BA03 flunisolide 35 (9.21) 22 (8.14) 32 (12.12) 31 (7.95)
R03BA05 fluticasone 87 (6.23) 35 (6.82) 41 (13.85) 38 (21.96) 32 (8.42) 22 (8.14) 70 (26.51) 74 (18.97)
R03BA08 ciclesonide 1 (0.07) 4 (1.05) 1 (0.25)
R03BC01 cromoglicic
acid
2 (0.14)
R03BC03 nedocromil 1 (0.07)
R03CC12 bambuterol 12 (0.86) 8 (1.55) 3 (0.76)
R03DA04 theophylline 91 (6.52) 24 (4.67) 7 (2.36) 22 (5.78) 8 (2.96)
R03DA05 aminophylline 4 (0.28) 8 (2.05)
R03DA11 doxofylline 30 (7.89) 13 (4.81) 2 (0.75) 6 (1.53)
R03DC01 zafirlukast 99 (7.1) 23 (4.48) 13 (4.39) 1 (0.26) 2 (0.74) 2 (0.51)
†
N, number of add-on or switch; ‡ATC, anatomical therapeutic classification.
A plausible explanation for our results is that for women in
fertile age, the role of leukotriene for asthma exacerbation is
of higher relevance than in male (Hanley, 1981; Eliasson et al.,
1986; Skobeloff et al., 1996; Nakasato et al., 1999). This biological
difference could have led women to have a higher benefit from
the anti-leukotriene therapy in terms of relieving asthma’ sign
and symptoms resulting in a more favorable prognosis. We
hypothesized that the observed gender differences were mediated
by sex steroids (Hanley, 1981; Eliasson et al., 1986; Skobeloff et al.,
1996; Nakasato et al., 1999).
In line with this hypothesis, it should be emphasized that
women in the fertile age, when compared to men, tend to
have especially during the preovulatory phase (Osborne et al.,
1998; Cydulka et al., 2001; Brenner et al., 2005; Ostrom, 2006;
Pereira Vega et al., 2010; Graziottin and Zanello, 2015; Graziottin
and Serafini, 2016) a different perception of their symptoms
which lead to a poorer control of asthma and to an increase in
asthma treatments and healthcare use (Pignataro et al., 2017).
Specifically, during preovulatory and perimenstrual phases when
serum estradiol levels decrease sharply after the prolonged peak,
there is a higher concentration of serum leukotriene C4 levels
which is associated with a higher risk of asthma exacerbation
(Skobeloff et al., 1996; Nakasato et al., 1999; Green et al., 2004;
Brenner et al., 2005; Matteis et al., 2014). We believed, therefore,
that when the impact of leukotriene was minimized by using a
leukotriene receptor antagonist, montelukast, women were more
prone to perceive the benefit of asthma medicines and therefore
persist more in treatment and request less add-on/switch or
rescue therapies than men.
We also believe that androgens could have played a key role
in gender differences for our study outcomes. In accordance
with our hypothesis, Pergola and colleagues proved that
testosterone and 5α-dihydrotestosterone were able to modulate
leukotriene biosynthesis by stimulating ERK which in turn
represses phospholipase D causing a reduced biosynthesis
of leukotriene by 5-lipoxygenase (Pergola et al., 2008, 2011).
Additionally, evidence from preclinical models shows an
impaired modulation of leukotriene pathway mediated by
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androgens in male rats and mice which unbalanced the rate of
severe asthma exacerbation between the two genders (Pace et al.,
2017). In particular, androgens by modulating the assembly
of the complex leukotriene-biosynthetic-5-lipoxygenase/5-
lipoxygenase–activating protein required a higher dosage of an
inhibitor of 5-lipoxygenase–activating protein which resulted
in a more efficient reduction of leukotriene B4 levels in female
mice and rats’ lung exudates when compared to male (Pace et al.,
2017). We believe that if aforementioned effects are directly
translatable in humans, male during the fertile age could have
benefitted less from an anti-leukotriene therapy given the impact
androgens on leukotriene pathway.
In accordance with aforementioned speculations on the
involvement of sex hormones for our results, we found that
in the Danish prepubertal pediatric cohort, there were no
statistically significant differences between male and female users
of montelukast for primary and secondary outcomes. In the
Italian prepubertal cohort instead, for our study outcomes,
associations were reversed or not statistically significant. In this
regard, it should be highlighted that as mentioned, both Danish
and Italian pediatric cohorts had a mean age that is compatible
with a prepubertal phase in which the level of sex steroids are
notoriously low (Swerdloff and Odell, 1975; Korth-Schutz et al.,
1976; Garnett et al., 2004; Courant et al., 2010; Albin et al., 2012).
These results are in line with those published by Johnston et al.,
which evidenced in a randomized clinical trial that montelukast
addition was beneficial in pre-pubertal boys and post-pubertal
girls with asthma. In particular, asthmatic boys aged 2–5 years
showed greater benefit frommontelukast addition if compared to
boys aged 0- to 14-year-olds; for girls instead, the beneficial effect
of montelukast addition was most evident in 10- to 14-year-olds
(Johnston et al., 2007).
We hypothesized, therefore, that in virtue of aforementioned
mechanisms, testosterone could have influenced the chance of
montelukast of properly relieve sign and symptoms of asthma
in male patients, and these phenomena could have resulted in
a lower probability of have a positive prognosis for our study
outcomes.
STRENGTHS AND LIMITATIONS
The major strength of this study is the confirmation of results
in two different European countries while the main limitation of
this study is its observational design, which does not exclude the
possibility of unmeasured confounders limiting the estimation
of causal effects. Limitations should include the lack of data
availability on hormone levels and lack of statistical power to
split cohorts into different age groups. Additionally, it should
be emphasized that the use of surrogate outcomes and registries
to investigate safety-related outcomes have intrinsic limitations
that have been described elsewhere (Boissel et al., 1992; Aronson,
2012; Thygesen and Ersbøll, 2014).
CONCLUSION
In Italian and Danish adults, male gender was associated with an
increased hazard of montelukast discontinuation, add-on/switch
to a long-term treatment for asthma following montelukast
withdrawal, and rescue therapy with oral corticosteroids or short-
acting β2 agonist when compared to the female gender. These
differences were lost or reversed in the pediatric population.
Despite more studies are necessary to clarify these associations,
our results could inspire researchers to investigate further the
beneficial effect of a possible gender-oriented pharmacological
treatment of asthma. In order to overcome the limitations of
this study we are now conducting a prospective cohort study in
collaboration with the Respiratory Department of the “Mauro
Scarlato” Hospital (Scafati, Italy).
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